Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab Plus Axitinib and Deferred Nephrectomy for Metastatic ccRCC
NCT06279403Phase 2Active, not recruiting
- Sponsor
- Renji Hospital
- Start
- Mar 2024
- Primary completion
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab, axitinib in clear cell renal cell carcinoma (ccRCC), sponsored by Renji Hospital. Started Mar 2024; status: active, not recruiting.
02
Drugs
toripalimabaxitinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT06279403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06279403.